Myocardial Perfusion in Type 2 Diabetes
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Metformin
Sponsored by

About this trial
This is an interventional diagnostic trial for Type 2 Diabetes focused on measuring Diabetes Mellitus, Myocardial perfusion imaging, Heart diseases, Echocardiography, Endothelium
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes mellitus
- Normal echocardiogram
- Absence of obstructive epicardial coronary disease
Exclusion Criteria:
- Obstructive coronary disease
- Heart valve disease
- COPD
- Cardiac Arrhythmias
- Cardiomyopathy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Diabetes
Control
Arm Description
Type 2 diabetes patients without obstructive coronary disease. Interventional group: lifestyle changes and treatment with metformin.
Control group - normal, healthy individuals.
Outcomes
Primary Outcome Measures
myocardial blood flow velocity, myocardial blood flow reserve
Secondary Outcome Measures
Full Information
NCT ID
NCT01043965
First Posted
January 6, 2010
Last Updated
January 6, 2010
Sponsor
University of Sao Paulo General Hospital
Collaborators
Fundação de Amparo à Pesquisa do Estado de São Paulo
1. Study Identification
Unique Protocol Identification Number
NCT01043965
Brief Title
Myocardial Perfusion in Type 2 Diabetes
Official Title
Evaluation of Myocardial Perfusion and Microvascular Reserve in Real-time Utilizing Myocardial Contrast Echocardiography in Type 2 Diabetes.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2005
Overall Recruitment Status
Completed
Study Start Date
August 2005 (undefined)
Primary Completion Date
August 2009 (Actual)
Study Completion Date
August 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of Sao Paulo General Hospital
Collaborators
Fundação de Amparo à Pesquisa do Estado de São Paulo
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The investigators aimed to evaluate microvascular circulation with novel method: real-time myocardial contrast echocardiography in patients with type 2 diabetes and normal coronary arteries.
Myocardial blood flow reserve will be determined by quantitative contrast Stress echocardiography. Diabetic individuals will be evaluate in a decompensated state (Phase 1) and after optimization of medical treatment four months later (Phase 2).
Detailed Description
Early stages of epicardial atherosclerosis in patients with type 2 diabetes are associated with an impairment in endothelium-dependent dilation of the coronary microvasculature, indicating that the pathophysiological consequences of atherosclerosis may extend into the coronary microcirculation.
The investigators will evaluate three parameters of myocardial quantification with contrast Stress echocardiography and correlate with HbA1C levels.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Diabetes Mellitus, Myocardial perfusion imaging, Heart diseases, Echocardiography, Endothelium
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
Investigator
Allocation
Non-Randomized
Enrollment
61 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diabetes
Arm Type
Active Comparator
Arm Description
Type 2 diabetes patients without obstructive coronary disease. Interventional group: lifestyle changes and treatment with metformin.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Control group - normal, healthy individuals.
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Glucophage
Intervention Description
Metformin 850mg
Primary Outcome Measure Information:
Title
myocardial blood flow velocity, myocardial blood flow reserve
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes mellitus
Normal echocardiogram
Absence of obstructive epicardial coronary disease
Exclusion Criteria:
Obstructive coronary disease
Heart valve disease
COPD
Cardiac Arrhythmias
Cardiomyopathy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wilson Mathias Jr, Md, PhD
Organizational Affiliation
Heart Institute - Sao Paulo - Brazil
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Myocardial Perfusion in Type 2 Diabetes
We'll reach out to this number within 24 hrs